NL-OMON30637已完成不适用
A First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Escalating Oral Doses of JNJ 28431754 in Healthy Male Subjects - N/A
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Healthy, non-smoking males, aged 18-55 years
排除标准
- •Positive FOBT at screening or admission (Day -1)
- •Positive H. pylori IgG Ab test result from the Chemiluminescence Immunoassay or urea breath test, at screening
- •History of disorders that are potential causes of occult GI bleeding
- •History of, or currently active, significant illness or medical disorders
- •Male subjects who are not sterile and are unwilling to use condoms for the duration of the study (and until 90 days after the last dose of study medication).
- •Tested positive for serology: hepatitis B surface antigen (HBsAg), hepatitis C antibodies (anti-HCV) or human immunodeficiency virus (HIV) antibodies.
研究者
相似试验
已完成
1 期
First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NOX-H94MedDRA - LLT 10002272 (Anämie / Anemia)D63Anaemia in chronic diseases classified elsewhereDRKS00003102OXXON Pharma AG64
进行中（未招募）
1 期
A study in healthy male volunteers to look at the safety and tolerability of the new test medicine GUB014295 and how it is taken up by the body when given as a single dose by injectioControlling obesityNutritional, Metabolic, EndocrineISRCTN85112396Gubra A/S48
已完成
2 期
A First in Human trial to study safety and tolerability of single rising intravitreal doses (oPen label, non-randomized, uncontrolled) and in Addition the early biological Response of mulTiple intravitreal doses (double-masked, RandomIzed, shamcontrolleD) of BI 765128 in panretinal photocoaGulation (PRP) treated diabetic rEtinopathy (DR) patients with diabetic macular ischemia (DMI) - the PARTRIDGE StudyDiabetic Macular IschemiaDMI10047061NL-OMON53613Boehringer Ingelheim1
进行中（未招募）
不适用
CBPR277X2101Part 2: Atopic Dermatitis (AD)Part 3: Netherton Syndrome (NS)MedDRA version: 14.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858MedDRA version: 14.1Level: PTClassification code 10062909Term: Netherton's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2011-000917-38-DEovartis Pharma Services AG85
进行中（未招募）
不适用
CBPR277X2101EUCTR2011-000917-38-NLovartis Pharma Services AG85